医学
艾塞那肽
心肌梗塞
心脏病学
内科学
心肌再灌注损伤
仰角(弹道)
再灌注损伤
ST段
糖尿病
缺血
2型糖尿病
内分泌学
几何学
数学
作者
Jacob Lønborg,Niels Vejlstrup,Henning Kelbæk,Hans Erik Bøtker,Won Yong Kim,Anders Bruun Mathiasen,Erik Jørgensen,Steffen Helqvist,Kari Saunamäki,Peter Clemmensen,Lene Holmvang,Leif Thuesen,Lars Romer Krusell,Jan Skov Jensen,Lars Køber,Marek Treiman,Jens J. Holst,Thomas Engstrøm
标识
DOI:10.1093/eurheartj/ehr309
摘要
AIMS: Exenatide, a glucagon-like-peptide-1 analogue, increases myocardial salvage in experimental settings with coronary occlusion and subsequent reperfusion. We evaluated the cardioprotective effect of exenatide at the time of reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). METHODS AND RESULTS: A total of 172 patients with STEMI and Thrombolysis in Myocardial Infarction flow 0/1 were randomly assigned to exenatide or placebo (saline) intravenously. Study treatment was commenced 15 min before intervention and maintained for 6 h after the procedure. The primary endpoint was salvage index calculated from myocardial area at risk (AAR), measured in the acute phase, and final infarct size measured 90 ± 21 days after pPCI by cardiac magnetic resonance (CMR). In 105 patients evaluated with CMR, a significantly larger salvage index was found in the exenatide group than in the placebo group (0.71 ± 0.13 vs. 0.62 ± 0.16; P= 0.003). Infarct size in relation to AAR was also smaller in the exenatide group (0.30 ± 0.15 vs. 0.39 ± 0.15; P= 0.003). In a regression analysis, there was a significant correlation between the infarct size and the AAR for both treatment groups and an analysis of covariance showed that datapoints in the exenatide group lay significantly lower than for the placebo group (P= 0.011). There was a trend towards smaller absolute infarct size in the exenatide group (13 ± 9 vs. 17 ± 14 g; P= 0.11). No difference was observed in left ventricular function or 30-day clinical events. No adverse effects of exenatide were observed. CONCLUSION: In patients with STEMI undergoing pPCI, administration of exenatide at the time of reperfusion increases myocardial salvage.
科研通智能强力驱动
Strongly Powered by AbleSci AI